# $\begin{array}{c} \bullet & \mathbf{B} & \mathbf{F} & \mathbf{F}$

## Notice to AGM for Biovica International AB

The Board of Directors of Biovica International AB, corporate identity number 556774-6150, hereby convenes the Annual General Meeting on 27 August 2020 at 16:00 in the company's premises at Dag Hammarskjölds väg 54B, Uppsala Science Park, Uppsala.

PRESS RELEASE

(+)

July 22, 2020

(+)(+)(+)(+)(+)

#### Registration / right to attend the meeting

Shareholders who wish to participate in the Annual General Meeting must be entered in the share register kept by Euroclear Sweden AB on Friday 21 August 2020 and no later than the said date notify their intention to participate in the Annual General Meeting according to one of the following alternatives: by letter to Biovica International AB. Cecilia Driving, Dag Hammarskjölds väg 54B, 752 37 Uppsala, by telephone 018 4444 830 or e-mail at info@biovica. com.

Complete summons is only available in Swedish.

#### Contact

Anders Rylander, CEO Phone: +46-18-444 48 35 E-mail: anders.rylander@biovica.com

Cecilia Driving, EVP CFO/HR/IR Phone +46-73-125 92 47 E-mail: cecilia.driving@biovica.com

### Biovica – Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

#### Attachments

Notice to AGM for Biovica International AB